Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Yes, research increasingly suggests that losing your sense of smell could be an early warning sign of brain disease. Multiple studies have found that anosmia—the partial or complete loss of smell—often precedes cognitive decline by months or even years, particularly in neurodegenerative diseases like Alzheimer’s and Parkinson’s. For example, a landmark study of cognitively normal older adults found that those with poor smell identification had triple the risk of developing cognitive impairment over five years.
This makes olfactory testing potentially valuable as a simple, non-invasive screening tool for people at risk of brain disease. The connection between smell and the brain is direct and intimate. The olfactory nerve runs directly from the nasal mucosa into the olfactory bulb, one of the brain’s oldest structures, bypassing the blood-brain barrier that blocks most other sensory pathways. This direct anatomical route means that whatever damages smell can also damage neighboring brain regions involved in memory and executive function.
Table of Contents
- Why Does Smell Loss Happen in Neurodegenerative Disease?
- The Evidence Linking Smell Loss to Cognitive Decline
- What the Research Shows About Parkinson’s Disease and Anosmia
- How Smell Testing Works as a Screening Tool
- Confounders and Why Smell Loss Isn’t Always a Brain Problem
- Smell Loss in Mild Cognitive Impairment and Early Alzheimer’s
- Clinical Implications and When to Seek Evaluation
Why Does Smell Loss Happen in Neurodegenerative Disease?
The mechanism behind anosmia in Alzheimer’s and Parkinson’s disease relates to the same pathology that damages other brain regions. In Alzheimer’s disease, amyloid plaques and tau tangles accumulate not just in the hippocampus and cortex, but also in the olfactory bulb and piriform cortex—brain areas essential for smell perception. In Parkinson’s disease, the loss of dopamine-producing neurons affects the olfactory system alongside the motor system, often causing smell impairment years before tremor or rigidity appears.
The olfactory epithelium itself may also show signs of neurodegeneration. Studies examining nasal tissue from Parkinson’s disease patients have found alpha-synuclein aggregates—the same protein accumulation seen in the brain—embedded in the lining of the nose. This suggests that smell loss isn’t just a consequence of central brain damage but may reflect systemic neurodegeneration affecting the entire olfactory pathway. Unlike most other senses, the olfactory system continuously regenerates its sensory neurons, which makes it vulnerable to ongoing pathological processes.
The Evidence Linking Smell Loss to Cognitive Decline
Multiple longitudinal studies have documented this connection. A 2008 study published in JAMA followed over 1,400 cognitively normal adults for five years and found that those in the lowest quartile of smell identification had a significantly higher risk of developing mild cognitive impairment—a precursor to dementia. Critically, this association remained strong even after controlling for age, sex, and apolipoprotein E (APOE) status, suggesting smell impairment is an independent risk marker, not merely a symptom of existing cognitive decline.
However, a major limitation is that smell loss is not a perfect predictor. Many older adults experience gradual anosmia without developing dementia, particularly due to normal aging, chronic rhinosinusitis, medication side effects, or previous viral infections like COVID-19. Smell loss is highly sensitive—catching many people at risk—but not highly specific, meaning it generates false positives. A person losing their sense of smell should not assume they will develop dementia, though they may benefit from more frequent cognitive monitoring and neuroprotective lifestyle interventions.
What the Research Shows About Parkinson’s Disease and Anosmia
In Parkinson’s disease, the relationship is even more compelling. Roughly 90% of people with Parkinson’s experience some degree of smell dysfunction, making it one of the disease’s earliest and most universal features. The smell loss in Parkinson’s typically appears before motor symptoms by months to years—and sometimes, smell impairment is the first detectable sign of the disease.
A 2011 study found that among people with isolated REM sleep behavior disorder (a Parkinson’s precursor), those with impaired smell had a much higher risk of developing motor symptoms within the next few years. This staging has practical implications. If a person reports progressive smell loss alongside subtle sleep disturbances or mild constipation, neurologists may initiate more intensive monitoring or recommend biomarker testing (like dopamine transporter imaging) to assess Parkinson’s risk. Yet even here, the warning isn’t absolute—some people with strong Parkinson’s risk factors maintain normal smell, and some with anosmia never develop the disease.
How Smell Testing Works as a Screening Tool
The University of Pennsylvania Smell Identification Test (UPSIT) is the most widely researched olfactory assessment in clinical practice. It presents 40 scratch-and-sniff items, each with four multiple-choice answers, and takes 10-15 minutes. A score below the 10th percentile for age and sex is considered abnormal. Alternative tests include the Brief Smell Identification Test (B-SIT), which uses 12 odors and is quicker, and the Sniffin’ Sticks test, used more commonly in Europe.
The trade-off with smell testing is practicality versus predictive power. While the UPSIT is validated and well-normed, it requires a quiet setting, clear nasal passages, and careful administration—conditions not always available in a busy primary care clinic. Simpler bedside tests (like presenting common odors) are easier but less reliable. Most research has focused on the UPSIT, so its predictive value is better established than for quicker alternatives, yet it’s more burdensome for routine screening.
Confounders and Why Smell Loss Isn’t Always a Brain Problem
Smell dysfunction has multiple causes, and distinguishing central (brain-related) from peripheral (nasal/sinus-related) anosmia is clinically important but sometimes difficult. Chronic rhinosinusitis, nasal polyps, allergic rhinitis, and deviated septum all impair smell without involving the brain. Medications including chemotherapy agents, topiramate (an antiepileptic), and certain antihistamines can dull the sense of smell. Age itself degrades olfaction, independent of neurodegeneration.
Previous upper respiratory infections, including COVID-19 in some cases, can cause lasting anosmia. A critical limitation is that the UPSIT cannot distinguish the anatomic cause of smell loss. A person with severe nasal obstruction and abnormal UPSIT scores may not be at elevated cognitive risk—their nose, not their brain, is the problem. Only neuroimaging, CSF biomarkers (like phosphorylated tau), or longitudinal cognitive testing can help clarify whether smell loss reflects neurodegenerative disease. This means smell testing alone is insufficient for diagnosis; it must be integrated into a fuller clinical assessment.
Smell Loss in Mild Cognitive Impairment and Early Alzheimer’s
In people already diagnosed with mild cognitive impairment (MCI) or early Alzheimer’s disease, the relationship between smell and cognition is especially robust. Studies show that MCI patients with anosmia tend to progress to dementia faster than those with normal smell.
In some cases, cognitive decline correlates with declining olfactory scores—as the disease advances, smell gets worse. Autopsy studies of Alzheimer’s brains show that the olfactory bulb often harbors early and abundant amyloid and tau pathology, suggesting smell loss reflects genuine neurodegeneration rather than coincidental aging. One striking example comes from a longitudinal study following MCI patients: those with both poor smell identification and low cerebrospinal fluid levels of amyloid-beta (a marker of Alzheimer’s pathology) had markedly higher risk of progression to full dementia within three years, compared to those with only one abnormality.
Clinical Implications and When to Seek Evaluation
If an older adult experiences progressive smell loss—especially if it develops over weeks to months and affects multiple odors—evaluation is warranted. A neurologist or primary care physician should first rule out reversible causes: nasal infection, allergy, medication side effects, or recent viral illness. A simple anterior rhinoscopy can detect gross obstruction.
If the nose is clear and smell loss is confirmed, cognitive screening with tests like the Montreal Cognitive Assessment (MoCA) is reasonable, followed by structural MRI or biomarker testing if cognitive concerns emerge. Notably, isolated smell loss in an otherwise cognitively normal 70-year-old is not an automatic reason for immediate dementia workup—olfactory aging is common. But if smell loss occurs alongside other subtle neurological changes—slowness, balance problems, sleep disturbances, memory complaints from a reliable informant—the constellation of findings warrants more thorough evaluation. The takeaway is that smell loss is a signal worth investigating in context, not a diagnosis in itself.
